ScreenerHero

MSLESatellos Bioscience Inc. Common Stock

NAS · US · Healthcare · Biotechnology · satellos.com
10.01USDMkt Cap: 212.38M $P/E: —

Satellos Bioscience Inc., a clinical-stage drug development company, focuses on restoring natural muscle repair and regeneration in degenerative muscle diseases in Canada, the United States, and Australia. The company us…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap212.38M $
Enterprise Value147.52M $
Revenue (TTM)—
Gross Profit-1.51M $
Net Income (TTM)-24.87M $
Revenue/Share—
Last Price10.01 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees18
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-3.62
PEG—
EV/EBITDA-4.12
EV/Revenue—
P/S—
P/B3.00
EPS (TTM)-1.95
EPS (Forward)-2.81
52W Range
9.80559% of range10.15
52W High10.15 USD
52W Low9.805 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-89.52%
ROA-78.00%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-23.60M $
CapEx (TTM)6.00K $
FCF Margin—
FCF Yield-8.05%
Net Debt-61.84M $
Net Debt/EBITDA1.73
Balance Sheet
Debt/Equity—
Current Ratio11.22
Quick Ratio10.69
Book Value/Sh3.392 USD
Cash/Share2.969 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateJan 30, 2026
Analyst Consensus
Rating1.0 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)27.67 USD
Upside (mean)+176.4%
Target Range20.00 USD – 40.00 USD
$20.00+176.4% to mean$40.00
# Analysts3
Ownership
Shares Out.21.22M
Float17.63M
Insiders6.48%
Institutions50.60%
Short Interest
Short Ratio1.2d
Short % Out.0.54%
Shares Short104.10K
Short (prev mo.)83.49K
Technical
SMA 508.421 (+18.9%)
SMA 2007.934 (+26.2%)
Beta—
S&P 52W Chg21.00%
Avg Vol (30d)18.99K
Avg Vol (10d)19.85K
Technical Indicators
RSI (14)58.8
MACD0.3441
MACD Signal0.4158
MACD Hist.-0.0717
BB Upper10.34 USD
BB Middle9.870 USD
BB Lower9.401 USD
BB Width9.51%
ATR (14)0.5664 USD
Vol Ratio (20d)0.71x